SCHEMBL13291069

SCHEMBL13291069

COc1nccc2oc(C(=O)Nc3ccc(C)cn3)c(NC(=O)c3ccc(C(=O)N(C)CCN(C)C)cc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.43
▸ NPC1 O15118 6/20 0.43
▸ KDM4E B2RXH2 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ GCK P35557 1/20 0.36
▸ TP53 P04637 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HTR1F P30939 1/20 0.36
▸ DEGS1 O15121 1/20 0.35
▸ F10 P00742 1/20 0.35
▸ MITF O75030 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13291041 0.91 F10 (0.43) RAB9ANPC1CASP3KMT2ASENP7
SCHEMBL13291053 0.90 RAB9A (0.46) RAB9ANPC1KDM4ECASP3KMT2A
SCHEMBL13291071 0.89 MAPT (0.41) RAB9ANPC1KDM4EKMT2ATP53
SCHEMBL13291065 0.84 RAB9A (0.46) RAB9ANPC1KDM4ECASP3KMT2A
SCHEMBL13291014 0.83 NPC1 (0.41) RAB9ANPC1KDM4ECASP3KMT2A
SCHEMBL13291040 0.81 F10 (0.49) RAB9ANPC1CASP3KMT2ASENP7
SCHEMBL13291062 0.79 MAPT (0.44) RAB9ANPC1KDM4EKMT2ATP53
SCHEMBL13291039 0.75 SMN1; SMN2 (0.46) RAB9ANPC1KDM4ECASP3SENP7
SCHEMBL13291016 0.75 NPC1 (0.44) RAB9ANPC1KDM4ECASP3KMT2A
SCHEMBL13291038 0.75 F10 (0.43) RAB9ANPC1CASP3KMT2ASENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 RAB9A 4692/4885NPC1 4426/4885KDM4E 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback